Home › Bio-Path Holdings To Initiate Development Of Liposomal Bcl-2 In Follicular Lymphoma
 

Keywords :   


Bio-Path Holdings To Initiate Development Of Liposomal Bcl-2 In Follicular Lymphoma

2014-12-29 02:22:44| drugdiscoveryonline Home Page

Bio-Path Holdings, Inc., (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, recently announced that it has initiated development of Liposomal Bcl-2 as a treatment for follicular lymphoma

Tags: development holdings initiate lymphoma

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
04.10Should you tip even if the service wasn't worth it?
04.10Hurricane Kirk Graphics
04.10Hurricane Kirk Forecast Discussion Number 22
04.10Tropical Storm Leslie Forecast Discussion Number 10
04.10Hurricane Kirk Wind Speed Probabilities Number 22
04.10Hurricane Kirk Public Advisory Number 22
04.10Summary for Hurricane Kirk (AT2/AL122024)
04.10Tropical Storm Leslie Public Advisory Number 10
More »